DIM
YMAB

DC Investments Management’s Y-mAbs Therapeutics YMAB Stock Holding History

DC Investments Management’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-25,000
Closed -$664K – 319
2018
Q3 		$664K Buy
+25,000
New +$636K 0.45% 36

Other funds holding YMAB

SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

DC Investments Management's YMAB Position: Q4 2018 in Review

DC Investments Management sold out of Y-mAbs Therapeutics (YMAB) in Q4 2018, closing a stake of 25,000 shares — an estimated $664K sold.

DC Investments Management first reported a position in YMAB in Q3 2018 and held it in 1 quarter. The position peaked at $664K in Q3 2018. 42 funds tracked by Wall St. Rank hold YMAB as of Q4 2018.

  • DC Investments Management reported no remaining Y-mAbs Therapeutics position as of Q4 2018 after selling out during the quarter.
  • DC Investments Management sold 25,000 Y-mAbs Therapeutics shares in Q4 2018, an estimated $664K.
  • DC Investments Management first reported a position in Y-mAbs Therapeutics in Q3 2018 and held it in 1 quarter.
  • DC Investments Management's Y-mAbs Therapeutics position peaked at $664K in Q3 2018.
  • 42 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q4 2018.

Based on DC Investments Management's 13F filing for Q4 2018, filed 8 Feb 2019.